Antitumor information factor array and use thereof

By constructing an informational bacteria array and utilizing the channel-forming domain of coliforms to bind with antibody mimics, the problem of multi-target intervention in existing tumor treatments has been solved, achieving highly efficient killing and inhibition of various tumors while avoiding drug resistance and toxic side effects.

CN122163760APending Publication Date: 2026-06-09MONOTREE FUTURE PHARMACEUTICAL TECHNOLOGY LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
MONOTREE FUTURE PHARMACEUTICAL TECHNOLOGY LTD
Filing Date
2026-02-13
Publication Date
2026-06-09

AI Technical Summary

Technical Problem

Existing cancer treatments are difficult to target multiple tumor targets and pathways simultaneously, leading to a high recurrence and metastasis rate. Furthermore, conventional drugs have significant toxicity, making it difficult to use multiple antibody drugs simultaneously in the same patient.

Method used

An informational microbelin array was designed, which forms a fusion protein capable of forming ion channels on the tumor cell membrane by linking the channel-forming domain of coliforms with antibody mimics that specifically recognize tumor cell antigens, thereby achieving simultaneous attack on multiple tumor targets.

Benefits of technology

This array can effectively kill various tumor cells, avoid drug resistance and escape, and shows significant growth inhibition without obvious toxic side effects. It is suitable for the treatment of various tumors such as pancreatic cancer and liver cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122163760A_ABST
    Figure CN122163760A_ABST
Patent Text Reader

Abstract

The application belongs to the field of biological medicine, and relates to an anti-tumor pheromone array and application thereof. A polypeptide composition is provided, which comprises forty-six polypeptides, and the amino acid sequences of the forty-six polypeptides are shown as SEQ ID NO:1-46. An anti-tumor drug is also provided, which comprises forty-six fusion proteins, and the forty-six fusion proteins are obtained by connecting the channel forming domain of colicin with the forty-six polypeptides with the amino acid sequences shown as SEQ ID NO:1-46. Experiments prove that the pheromone array composed of the forty-six fusion proteins shows extremely significant growth inhibition and killing effects on pancreatic cancer cells and liver cancer cell-derived tumor models, and does not have any toxic side effects.
Need to check novelty before this filing date? Find Prior Art